EGFR and non-small cell lung carcinoma: What is activity of treatment with high-dose third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patients with untreated EGFR-variant non–small cell lung cancer (NSCLC) and brain metastases?